Navigation Links
Clinical Operations Executive, Hassan Movahhed, Joins NDA Partners as Expert Consultant
Date:8/21/2020

NDA Partners Chairman Carl Peck, MD, announced today that Hassan Movahhed, a Clinical Operations executive with expertise in clinical trial planning and feasibility, regulatory inspection readiness, and clinical investigator and CRO management, has joined the firm as an Expert Consultant. Throughout his career, Mr. Movahhed has helped design and manage oncology, neurology, cardiovascular, and anti-infective clinical trials and has prepared for pre-approval regulatory inspections.

Prior to joining NDA Partners, Mr. Movahhed served in Vice President or Senior Vice President roles at several companies including Exelixis, Forty-Seven, Inc., United Therapeutics, Elan, Geron, and Threshold Pharmaceuticals. He was formerly Senior Director and Head of US Development Operations and Clinical Affairs at Amgen and Senior Director of Clinical Operations at ICOS. In his early career, he served in roles of increasing responsibility at Bristol-Myers Squibb in infectious disease clinical research and drug pharmacokinetics and metabolism research.

“Mr. Movahhed’s extensive background in clinical operations will bring great value to our pharmaceutical clients who are conducting clinical trials in a variety of therapeutic areas including oncology, neurology, and cardiology. We are pleased to welcome him to NDA Partners,” said Dr. Peck.

Mr. Movahhed earned a master’s degree in biology and bachelor’s degree in zoology from the University of Michigan.

About NDA Partners
NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.

Contact
Earle Martin, Chief Executive Officer
Office: 540-738-2550
MartinEarle@ndapartners.com

Read the full story at https://www.prweb.com/releases/clinical_operations_executive_hassan_movahhed_joins_nda_partners_as_expert_consultant/prweb17312597.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer
2. Clinical Tests Demonstrate Long-Term Effectiveness of Oral Glutathione Supplements - Kyowa Study
3. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
4. Center for Clinical and Translational Science awards new pilot grants
5. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
6. Inflection Biosciences licenses preclinical oncology programs from the CNIO
7. New sickle cell anemia therapy advances to Phase II clinical trials
8. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
9. Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators
10. With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
11. DO-HEALTH a multi-center clinical trial on healthy ageing achieves first milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2020)... ... July 21, 2020 , ... USDM Life Sciences , ... announces a new solution to manage regulated workloads on Microsoft Azure. , Regulated ... stack complies with FDA and global regulations. USDM's new managed service for regulated ...
(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. While ... global economic downturn will only increase price pressures overall for the industry. The era ... from every product launch is critical. However, history shows that only a third of ...
(Date:7/10/2020)... ... ... Today CJ BIO announced the first in a series of Food Ingredient ... that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range of ... 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual Meeting ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... , ... July 29, 2020 , ... ... announced the launch of its new tagline, “BUILDING FOR LIFE.” The adoption of ... and around the globe, requiring fast track capacity to provide patients with urgently ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... 200 of the top radiation centers in 16 countries, has reached its 20th ... SDX® is now in routine use at top universities including University of Pennsylvania, ...
(Date:7/18/2020)... ... 16, 2020 , ... Medial EarlySign , a leader ... of high-burden diseases, and Centric Consulting, a business and technology consulting firm, today ... data in order to identify and prioritize patients for care. , Combining Centric’s ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., ... hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of ...
Breaking Biology Technology: